Liquidia Corporation Common Stock (LQDA)
Liquidia Corporation (LQDA) is a biotechnology company focused on the development and commercialization of innovative products using its proprietary PRINT (Particle Replication in Non-wetting Templates) technology. The company's primary areas of interest include treatments in the fields of pulmonary, infectious, and other specialized diseases. Liquidia aims to improve drug delivery and therapeutic outcomes through its advanced particle engineering platform.
Company News
Liquidia Corporation will present two oral presentations at the CHEST 2025 annual meeting, focusing on clinical data from its ASCENT trial for LIQ861 DPI treprostinil in pulmonary hypertension-interstitial lung disease (PH-ILD) patients, highlighting safety and exploratory efficacy data.
The Pulmonary Hypertension associated with Interstitial Lung Disease (PH-ILD) market is expected to grow significantly between 2025-2034, driven by improved diagnostic techniques, disease recognition, and emerging therapies targeting functional improvement and disease progression.
Liquidia Corp's Chief Medical Officer, Rajeev Saggar, has sold 1,470 shares of the company's common stock for $18,419, pursuant to a pre-scheduled 10b5-1 trading plan. The sale was to cover taxes associated with the vesting of restricted stock units.
MannKind's long-term liabilities exceed its assets, posing potential financial risks. Learn why MNKD stock is a Buy.
Liquidia Technologies (LQDA) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.